Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B
Open Access
- 28 September 2010
- Vol. 2 (10) , 2169-2195
- https://doi.org/10.3390/v2102169
Abstract
More than 20 years after the identification of the hepatitis C virus (HCV) as a novel human pathogen, the only approved treatment remains a combination of pegylated interferon-α and ribavirin. This rather non-specific therapy is associated with severe side effects and by far not everyone benefits from treatment. Recently, progress has been made in the development of specifically targeted antiviral therapy for HCV (STAT-C). A major target for such direct acting antivirals (DAAs) is the HCV RNA-dependent RNA polymerase or non-structural protein 5B (NS5B), which is essential for viral replication. This review will examine the current state of development of inhibitors targeting the polymerase and issues such as the emergence of antiviral resistance during treatment, as well as strategies to address this problem.Keywords
This publication has 113 references indexed in Scilit:
- Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C VirusScience Translational Medicine, 2010
- Slow Binding Inhibition and Mechanism of Resistance of Non-nucleoside Polymerase Inhibitors of Hepatitis C VirusJournal of Biological Chemistry, 2009
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionNew England Journal of Medicine, 2009
- Delayed Chain Termination Protects the Anti-hepatitis B Virus Drug Entecavir from Excision by HIV-1 Reverse TranscriptaseJournal of Biological Chemistry, 2008
- Hepatitis C Virus NS5B Polymerase Exhibits Distinct Nucleotide Requirements for Initiation and ElongationJournal of Biological Chemistry, 2008
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patientsHepatology, 2008
- High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutationsProceedings of the National Academy of Sciences, 2008
- Pyrophosphorolytic Excision of Nonobligate Chain Terminators by Hepatitis C Virus NS5B PolymeraseAntimicrobial Agents and Chemotherapy, 2007
- General Catalytic Deficiency of Hepatitis C Virus RNA Polymerase with an S282T Mutation and Mutually Exclusive Resistance towards 2′-Modified Nucleotide AnaloguesAntimicrobial Agents and Chemotherapy, 2006
- UCSF Chimera—A visualization system for exploratory research and analysisJournal of Computational Chemistry, 2004